Kolesterolsænkende behandling med PCSK9-inhibitorer
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Kolesterolsænkende behandling med PCSK9-inhibitorer. / Røder, Michael E; Hildebrandt, Per; Storgaard, Heidi; Heitmann, Merete.
I: Ugeskrift for Laeger, Bind 180, Nr. 20A, V11170831, 2018.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Kolesterolsænkende behandling med PCSK9-inhibitorer
AU - Røder, Michael E
AU - Hildebrandt, Per
AU - Storgaard, Heidi
AU - Heitmann, Merete
PY - 2018
Y1 - 2018
N2 - Monoclonal antibodies inhibiting proprotein convertase subtilisin-kexin type 9 constitute a new class of lipid-lowering drugs. Currently, evolocumab and alirocumab are marketed. A recent cardiovascular outcome study with evolocumab has shown a cardiovascular (CV) event reduction of 15% in high-risk individuals at very low levels of low-density lipoproteins. The adverse event profile up to two years is mild. Treatment is very costly, and data on CV endpoints are still limited. Treatment is restricted to patients at very high risk of getting CV diseases and on a maximal tolerated statin and ezetimibe treatment in addition to dietary intervention.
AB - Monoclonal antibodies inhibiting proprotein convertase subtilisin-kexin type 9 constitute a new class of lipid-lowering drugs. Currently, evolocumab and alirocumab are marketed. A recent cardiovascular outcome study with evolocumab has shown a cardiovascular (CV) event reduction of 15% in high-risk individuals at very low levels of low-density lipoproteins. The adverse event profile up to two years is mild. Treatment is very costly, and data on CV endpoints are still limited. Treatment is restricted to patients at very high risk of getting CV diseases and on a maximal tolerated statin and ezetimibe treatment in addition to dietary intervention.
M3 - Tidsskriftartikel
C2 - 30274588
VL - 180
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 20A
M1 - V11170831
ER -
ID: 221828540